ClinicalTrials.gg
CompletedNCT07669506NuvastaticTMUpdated Jun 25, 2026

A Study to Evaluate the Efficacy and Safety of Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA) in Patient With Breast Cancer Undergoing Chemotherapy

A Phase 3 interventional study of Nuvastatic ™ and Placebo in Breast Neoplasms, Fatigue and Quality of Life, sponsored by Natureceuticals Sdn Bhd. Completed at 7 sites in India. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Natureceuticals Sdn Bhd · Phase 3, Interventional, and Supportive care

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jun 2025, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Breast Neoplasms with a site in India — 20 open to participants now, 53 under way, 37 of them phase 3. Breast Neoplasms · India.

Enrollment
114th of 161
180 · median 333
Started
2025
with 12 others
Phase 3
84 of 182
11 open now
Registered
179th of 182
by date

Among the 182 studies in Breast Neoplasms with a site in India, this one is the 114th largest by enrollment of the 161 interventional ones that give a count, is one of 13 that started in 2025, is one of 84 in phase 3, and was the 179th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 182 studies in Breast Neoplasms with a site in India are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Breast Neoplasms with a site in India, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether Nuvastatic™ can reduce cancer-related fatigue and improve quality of life in adult female patients with breast cancer undergoing standard chemotherapy.

The main questions it aims to answer are:

Does Nuvastatic™ reduce cancer-related fatigue as measured by change in the Brief Fatigue Inventory (BFI) from baseline to end of treatment? Does Nuvastatic™ improve quality of life, safety outcomes, and clinical parameters compared with placebo during chemotherapy?

Researchers will compare patients receiving Nuvastatic™ plus standard chemotherapy with patients receiving placebo plus standard chemotherapy to see if Nuvastatic™ leads to greater reductions in fatigue, improved quality of life, and acceptable safety while undergoing treatment.

Participants will:

  • Receive Nuvastatic™ or matching placebo as a 1000 mg effervescent sachet taken three times daily after meals for three chemotherapy cycles
  • Continue their standard-of-care chemotherapy as prescribed by their treating physician
  • Complete fatigue and quality-of-life questionnaires (BFI, SF-36, EORTC QLQ-C30)
  • Undergo routine clinical assessments, laboratory tests, ECGs, and safety monitoring
  • Undergo CT imaging for tumor response assessment according to RECIST 1.1
03

Conditions studied

  • Breast Neoplasms
  • Fatigue
  • Quality of Life
  • Chemotherapy, Adjuvant

Keywords

  • Breast Cancer
  • Cancer-Related Fatigue
  • Chemotherapy
  • Nuvastatic™
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female Patients aged ≥ 18 years and ≤65 years who are willing to voluntarily provide consent for participation in the study.
  2. Confirm diagnosis of Breast cancer as per the available Report.
  3. (ECOG) performance status of 0-2 at Screening.
  4. The patient has stable (≥ 9 g/dL) throughout the screening.
  5. ≥ 6 months, as per Investigator's judgment
  6. Patients with co-morbidities or medical conditions including Type 2 DM, hypertension and are deem stable by the investigator can be included in the study
  7. At screening patient with stable fatigue, has a newly developed fatigue OR worsening of fatigue scoring as assessed by BFI should be included.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have any untreated reversible medical condition which may cause fatigue (e.g. major metabolic or electrolyte disturbance, active infection, endocrine abnormalities) as per the Investigator's clinical judgement.
  2. Patient who have stage IV Disease
  3. Female patients who are pregnant or breast-feeding.
  4. Patients with known virus, virus, infection.
  5. Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the Investigator.
  6. Patients with uncontrolled pain, who in the opinion of the Investigator are not eligible for the study. '
  7. Patients with planned therapy or treatment with another agent.
  8. Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an Investigational agent, other than as specified by this protocol, during the study period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    1000mg sachet effervescent powder Placebo (1 sachet X 3 times a day)

    Drug: Placebo

  • Experimental
    Nuvastatic ™

    1000mg sachet effervescent powder Nuvastatic ™ (1 sachet X 3 times a day)

    Drug: Nuvastatic ™

Interventions

  • DrugNuvastatic ™

    Greenhouse-sourced extract 1000mg sachet, or openfield extract 1000mg sachet

  • DrugPlacebo

    greenhouse-sourced extract 1000mg sachet, or openfield extract 1000mg sachet

06

What researchers measure

Primary outcomes

  1. Change in Brief Fatigue Inventory (BFI) score

    The primary outcome measure was the intra-individual changes in the Brief Fatigue Inventory (BFI) fatigue scale and Visual Analogue Fatigue Scale (VAFS).

    Time frame: At baseline until end of treatment at 12 weeks

Secondary outcomes

  1. Overall QoL improvement using the medical outcome scale Short Form-36 (SF-36). ECOG scores were compared at baseline and at end of the study.

    Secondary Outcome Measures are: Fatigue assessment using SF-36 Questionnaire from screening to EOT. Change in Global Health Status/QoL score as measured by EORTC QLQ-C30 from screening to EOT. Incidence of adverse events (AEs) graded according to CTCAE v5.0. Tumor response assessed by RECIST 1.1 criteria from baseline to EOT.

    Time frame: At baseline and end of treatment at 12 weeks

  2. Changes in biomarkers

    Change in serum CEA (ng/mL) and CA15-3 (U/mL) levels from screening to EOT. Change in laboratory parameters from screening to EOT.

    Time frame: At baseline and end of treatment at 12 weeks

Other outcomes

  1. Exploratory biomarker

    To investigate whether urinary F2-isoprostane (F2-IsoP) excretion correlates with the severity of cancer-related fatigue (CRF) in patients undergoing chemotherapy

    Time frame: at baseline and end of treatment at 12 weeks

07

Study locations

7 sites
  • Department of Medical Oncology (In Charge - Oncology Unit), Govt. Medical College & Govt. General Hospital,
    Srikakulam, Andhra Pradesh 532001, India
  • Hanji Cancer Centre
    Belagavi, Karnataka 590006, India
  • K.R. Hospital, Mysore Medical College & Research Institute
    Mysuru, Karnataka 570001, India
  • Onco-Life Cancer Centre
    Satara, Maharashtra 415519, India
  • Onco-Life Cancer Centre, Pvt. Ltd (Talegaon General Hospital)
    Talegaon Dābhāde, Maharashtra 410506, India
  • Siddharth Gupta Memorial Cancer Hospital (A Unit of Acharya Vinoba Bhave Rural Hospital)
    Wardha, Maharashtra 442004, India
  • Avicenna Hospital
    Lucknow, Uttar Pradesh 226016, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Apr 2026, 10 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 10 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Jun 25, 2026
StartActual
Jun 17, 2025
Primary completionActual
Apr 25, 2026
CompletionActual
Jun 15, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07669506
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jun 17, 2025
Primary completion
Apr 25, 2026
Completion
Jun 15, 2026
Last update
Jun 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion